Tecentriq SC (atezolizumab)
pCPA File Number:
22700
Negotiation Status:
Concluded with an LOI
Indication(s):
for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis and ulcerative colitis
Sponsor/Manufacturer:
Hoffmann-La Roche Ltd.
CDA-AMC Project Number:
Not Applicable
pCPA Engagement Letter Issued:
Negotiation Process Concluded: